Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.72 |
| ▸ | CTSS | P25774 | 10/20 | 0.70 |
| ▸ | CTSK | P43235 | 9/20 | 0.70 |
| ▸ | CTSB | P07858 | 4/20 | 0.70 |
| ▸ | CTSL | P07711 | 3/20 | 0.70 |
| ▸ | AKT1 | P31749 | 1/20 | 0.60 |
| ▸ | ACE | P12821 | 1/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | REN | P00797 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9610766 | 1.00 | HDAC8 (0.72) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL3667404 | 0.93 | HDAC8 (0.64) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL3667405 | 0.93 | HDAC8 (0.64) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL3007610 | 0.92 | HDAC8 (0.63) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL31075430 | 0.92 | CTSS (0.65) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL23477265 | 0.92 | HDAC8 (0.66) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL3006410 | 0.92 | HDAC8 (0.63) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL30134871 | 0.92 | HDAC8 (0.66) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL3006406 | 0.92 | HDAC8 (0.63) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL3007613 | 0.92 | HDAC8 (0.63) | HDAC8CTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674144-B2 | Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-03-18 | — | — | US | disclosed |
| US-8674144-B2 | Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20120136176-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-1299426-B1 | IMPROVED MICROGELS AND FILMS | FRAUNHOFER GES FORSCHUNG (DE) | 2009-04-08 | — | — | EP | disclosed |
| CN-1264817-C | Certain cyclic thio substitued acylaminoacid amide derivatives | NOVARTIS AG (CH) | 2006-07-19 | — | — | CN | disclosed |
| US-RE39088-E1 | Amide compounds and use of the same | JAPAN TOBACCO, INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| EP-0849256-B1 | AMIDE COMPOUNDS AND USE OF THE SAME | JAPAN TOBACCO INC (JP) | 2005-06-08 | — | — | EP | disclosed |
| EP-0966439-B1 | CERTAIN CYCLIC THIO SUBSTITUTED ACYLAMINOACID AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2003-06-04 | — | — | EP | disclosed |
| EP-1304322-A2 | Carboxylic acid compound and use thereof | Japan Tobacco Inc. (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6420561-B1 | Amide compounds and use thereof | JAPAN TOBACCO INC. (JP) | 2002-07-16 | — | — | US | disclosed |
| US-6201133-B1 | FOR INHIBITING MATRIX-DEGRADING METALLOPROTEINASES IN MAMMALS, TREATING TNF ALPHA AND MATRIX METALLOPROTEINASE DEPENDENT DISEASES OR CONDITIONS, CANCER | NOVARTIS AG (CH) | 2001-03-13 | — | — | US | disclosed |
| US-6174887-B1 | Amide compounds and use of the same | JAPAN TOBACCO INC. (JP) | 2001-01-16 | — | — | US | disclosed |
| CN-1251092-A | Certain cyclic thio substitued acylaminoacid amide derivatives | NOVARTIS AG (CH) | 2000-04-19 | — | — | CN | disclosed |
| US-6034136-A | METALLOPROTEINASE INHIBITOR | NOVARTIS AG (CH) | 2000-03-07 | — | — | US | disclosed |
| EP-0966439-A1 | CERTAIN CYCLIC THIO SUBSTITUTED ACYLAMINOACID AMIDE DERIVATIVES | Novartis AG (CH) | 1999-12-29 | — | — | EP | disclosed |
| EP-0719251-B1 | BICYCLO (2.2.2) OCTANE DERIVATIVES CHOLECYSTOKININ AND/OR GASTRIN ANTAGONISTS | BLACK JAMES FOUNDATION (GB) | 1998-12-09 | — | — | EP | disclosed |
| WO-1998042662-A1 | CERTAIN CYCLIC THIO SUBSTITUTED ACYLAMINOACID AMIDE DERIVATIVES | NOVARTIS AG (CH) | 1998-10-01 | — | — | WO | disclosed |
| EP-0849256-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | Japan Tobacco Inc. (JP) | 1998-06-24 | — | — | EP | disclosed |
| US-5514683-A | LIGANDS FKOR CHOLECYSTOKININ OR GASTRIN RECEPTORS | JAMES BLACK FOUNDATION LIMITED (GB) | 1996-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136176-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | HMOX1, HIRA, HRH1 | HDAC8 2466/4885CTSS 1979/4885CTSK 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.